Goldman Sachs
NYMX

Goldman Sachs’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Goldman Sachs’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,084
Closed -$4.2K – 6073
2023
Q2 		$4.2K Buy
22,084
+2,100
+11% +$827 ﹤0.01% 5643
2023
Q1 		$6.79K Hold
19,984
– – ﹤0.01% 5773
2022
Q4 		$6.46K Sell
19,984
-1,238
-6% -$448 ﹤0.01% 5792
2022
Q3 		$9K Sell
21,222
-2,560
-11% -$1.02K ﹤0.01% 6038
2022
Q2 		$10K Sell
23,782
-123
-0.5% -$113 ﹤0.01% 6272
2022
Q1 		$30K Sell
23,905
-477
-2% -$736 ﹤0.01% 6352
2021
Q4 		$32K Buy
24,382
+1
+0% +$2 ﹤0.01% 6322
2021
Q3 		$50K Sell
24,381
-24,355
-50% -$43.2K ﹤0.01% 6049
2021
Q2 		$77K Buy
48,736
+20,236
+71% +$37.5K ﹤0.01% 6009
2021
Q1 		$63K Buy
28,500
+3,028
+12% +$7.98K ﹤0.01% 5912
2020
Q4 		$63K Buy
25,472
+1,858
+8% +$4.11K ﹤0.01% 5349
2020
Q3 		$58K Sell
23,614
-630
-3% -$1.83K ﹤0.01% 5169
2020
Q2 		$86K Sell
24,244
-136,752
-85% -$433K ﹤0.01% 5011
2020
Q1 		$377K Buy
160,996
+119,718
+290% +$336K ﹤0.01% 4381
2019
Q4 		$91K Buy
41,278
+8,900
+27% +$17.6K ﹤0.01% 5056
2019
Q3 		$59K Sell
32,378
-125,787
-80% -$220K ﹤0.01% 5025
2019
Q2 		$229K Buy
158,165
+99,580
+170% +$174K ﹤0.01% 4733
2019
Q1 		$115K Buy
58,585
+15,135
+35% +$32.1K ﹤0.01% 4909
2018
Q4 		$57K Sell
43,450
-7,001
-14% -$12.8K ﹤0.01% 5080
2018
Q3 		$124K Buy
50,451
+7,246
+17% +$21.4K ﹤0.01% 5069
2018
Q2 		$145K Buy
43,205
+30,502
+240% +$117K ﹤0.01% 5104
2018
Q1 		$54K Buy
+12,703
New +$44K ﹤0.01% 5459
2017
Q4 		– Sell
-13,931
Closed -$53K – 6744
2017
Q3 		$53K Sell
13,931
-12,725
-48% -$48.2K ﹤0.01% 6245
2017
Q2 		$117K Buy
+26,656
New +$109K ﹤0.01% 6058
2015
Q4 		– Sell
-10,487
Closed -$36K – 7412
2015
Q3 		$36K Buy
+10,487
New +$24.4K ﹤0.01% 6892

Other funds holding NYMX

DDC
DF Dent & Co Baltimore, Maryland $5.22B AUM 2.07% 1-Year Est. Return
FCFC
First Citizens Financial Corp Mason City, Iowa $239M AUM 26.56% 1-Year Est. Return
CAM
Cubic Asset Management Boston, Massachusetts $422M AUM 29.18% 1-Year Est. Return
ODIJL
One Day In July LLC Burlington, Vermont $1.25B AUM 12.08% 1-Year Est. Return

Goldman Sachs's NYMX Position: Q3 2023 in Review

Goldman Sachs sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2023, closing a stake of 22,084 shares — an estimated $4.2K sold.

Goldman Sachs first reported a position in NYMX in Q3 2015 and held it in 25 quarters. The position peaked at $377K in Q1 2020. 5 funds tracked by Wall St. Rank hold NYMX as of Q3 2023.

  • Goldman Sachs reported no remaining Nymox Pharmaceutical Corp position as of Q3 2023 after selling out during the quarter.
  • Goldman Sachs sold 22,084 Nymox Pharmaceutical Corp shares in Q3 2023, an estimated $4.2K.
  • Goldman Sachs first reported a position in Nymox Pharmaceutical Corp in Q3 2015 and held it in 25 quarters.
  • Goldman Sachs's Nymox Pharmaceutical Corp position peaked at $377K in Q1 2020.
  • 5 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2023.

Based on Goldman Sachs's 13F filing for Q3 2023, filed 14 Nov 2023.